Enterolactone concentrations and prognosis after postmenopausal breast cancer: Assessment of effect modification and meta-analysis

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 923-933

  Seibold, Petra ^a   Vrieling, Alina ^a,b   Johnson, Theron S ^a   Buck, Katharina ^a   Behrens, Sabine ^a   Kaaks, Rudolf ^a   Linseisen, Jakob ^c   Obi, Nadia ^d   Heinz, Judith ^d   Flesch Janys, Dieter ^d   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

breast cancer mortality; enterolactone; lignans; phytoestrogens

Indexed keywords

ENTEROLACTONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE; TAMOXIFEN;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE FREE SURVIVAL; DISTANT DISEASE FREE SURVIVAL; EDUCATIONAL STATUS; FOLLOW UP; HORMONAL THERAPY; HUMAN; LIFESTYLE; META ANALYSIS; METASTASIS; OBESITY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENCE RISK;

BREAST CANCER MORTALITY; ENTEROLACTONE; LIGNANS; PHYTOESTROGENS;

4-BUTYROLACTONE; AGED; BODY MASS INDEX; BREAST NEOPLASMS; DIET; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; LIFE STYLE; LIGNANS; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902256263     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28729     Document Type: Article

References (32)

1. Fletcher RJ,. Food sources of phyto-oestrogens and their precursors in Europe. Br J Nutr 2003; 89 (Suppl 1): S39-S43.
2. Zamora-Ros R, Knaze V, Lujan-Barroso L, et al. Dietary intakes and food sources of phytoestrogens in the European prospective investigation into cancer and nutrition (EPIC) 24-hour dietary recall cohort. Eur J Clin Nutr 2012; 66: 932-41.
3. Wang LQ,. Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777: 289-309.
4. Adlercreutz H,. Lignans and human health. Crit Rev Clin Lab Sci 2007; 44: 483-525.
5. Truan JS, Chen JM, Thompson LU,. Comparative effects of sesame seed lignan and flaxseed lignan in reducing the growth of human breast tumors (MCF-7) at high levels of circulating estrogen in athymic mice. Nutr Cancer 2012; 64: 65-71.
6. Buck K, Zaineddin AK, Vrieling A, et al. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr 2010; 92: 141-53.
7. McCann SE, Hootman KC, Weaver AM, et al. Dietary intakes of total and specific lignans are associated with clinical breast tumor characteristics. J Nutr 2012; 142: 91-8.
8. Ha TC, Lyons-Wall PM, Moore DE, et al. Phytoestrogens and indicators of breast cancer prognosis. Nutr Cancer 2006; 56: 3-10.
9. Buck K, Vrieling A, Zaineddin AK, et al. Serum enterolactone and prognosis of postmenopausal breast cancer. J Clin Oncol 2011; 29: 3730-8.
10. Guglielmini P, Rubagotti A, Boccardo F,. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. Breast Cancer Res Treat 2012; 132: 661-8.
11. Olsen A, Christensen J, Knudsen KE, et al. Prediagnostic plasma enterolactone levels and mortality among women with breast cancer. Breast Cancer Res Treat 2011; 128: 883-9.
12. Buck K, Zaineddin AK, Vrieling A, et al. Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 2011; 105: 1151-7.
13. McCann SE, Thompson LU, Nie J, et al. Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 2010; 122: 229-35.
14. Fink BN, Steck SE, Wolff MS, et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev 2007; 16: 2285-92.
15. Patterson RE,. Flaxseed and breast cancer: what should we tell our patients? J Clin Oncol 2011; 29: 3723-4.
16. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008; 123: 933-41.
17. Vrieling A, Buck K, Heinz J, et al. Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res Treat 2012; 136: 195-207.
18. Adlercreutz H, Wang GJ, Lapcik O, et al. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 1998; 265: 208-15.
19. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22: 1736-47.
20. Lin DY, Wei LJ, Ying Z,. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80: 557-72.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009; 339: b2535.
22. Dersimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
23. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11: 193-206.
24. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
26. Mense SM, Hei TK, Ganju RK, et al. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect 2008; 116: 426-33.
27. Mali AV, Wagh UV, Hegde MV, et al. In vitro anti-metastatic activity of enterolactone, a mammalian lignan derived from flax lignan, and down-regulation of matrix metalloproteinases in MCF-7 and MDA MB 231 cell lines. Indian J Cancer 2012; 49: 181-7.
28. Thompson LU, Chen JM, Li T, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 2005; 11: 3828-35.
29. Kilkkinen A, Stumpf K, Pietinen P, et al. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001; 73: 1094-100.
30. Swann R, Perkins KA, Velentzis LS, et al. The DietCompLyf study: a prospective cohort study of breast cancer survival and phytoestrogen consumption. Maturitas 2013; 75: 232-40.
31. Mabrok HB, Klopfleisch R, Ghanem KZ, et al. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 2012; 33: 203-8.
32. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, et al. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 1998; 7: 885-9.